WHITE SULPHUR SPRINGS, W.Va. (WVDN) — The Food and Drug Administration (FDA) has issued an urgent notification regarding mammography services at The Greenbrier Clinic, citing significant quality deficiencies that may have compromised the accuracy of breast cancer screenings for thousands of patients.
The clinic has been ordered to immediately cease all mammography operations. The suspension follows an evaluation by the American College of Radiology (ACR), which determined the facility failed to meet clinical image quality standards required under the Mammography Quality Standards Act (MQSA).
The deficiency period spans more than two years. Any patient who received a mammogram at The Greenbrier Clinic between October 28, 2023, and February 26, 2026, is urged to take immediate action.
In a certified letter sent to affected patients on March 23, 2026, Dr. Henry Setliff, the clinic’s radiologist, acknowledged the “serious concern” raised by the FDA. While the notification does not confirm that every test result was incorrect, it warns that the quality of images produced during this window was insufficient to guarantee a reliable diagnosis.
Despite the clinic’s efforts to notify patients via certified mail, The West Virginia Daily News has received report from citizens that many individuals affected by the deficiency have yet to receive their letters.
Officials recommend the following steps for anyone who visited the clinic for a mammogram during the affected timeframe:
Consult Your Physician: Discuss these findings with your primary care provider or OB-GYN to determine if a repeat mammogram is necessary.
Request Your Records: Patients have the right to request their original mammography films and reports to take to another facility for a second opinion or comparison.
Contact the Clinic: If you were a patient between October 2023 and February 2026 and have not received a certified letter, contact The Greenbrier Clinic directly to confirm your status and update your contact information.
The Greenbrier Clinic is reportedly working with the ACR and the FDA to address the technical issues and regain accreditation. However, there is currently no estimated date for when mammography services will resume at the facility.
